Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant gefitinib followed by platinum-taxane chemotherapy with intercalated gefitinib in EGFR-mutant NSCLC
2014-005595-28Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Jul 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib, docetaxel, cisplatin, paclitaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Primary endpoint: Pathologic complete remission rate. Started Jul 2015; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005595-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005595-28.